9:00am - 5:00pm

Our Opening Hours Mon. - Fri.


Call Us For Free Consultation




APG-2449 in Patients With Advanced Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > APG-2449 in Patients With Advanced Solid Tumors

APG-2449 in Patients With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition: Advanced Solid Cancer

Estimated Enrollment: 40

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Maximum Tolerated Dose (MTD),  Recommended Phase 2 dose (RP2D),  Maximum plasma concentration (Cmax), Area under the plasma concentration versus time curve (AUC)

Interventions: APG-2449,


Study Type: Interventional

Study Design: Intervention Model: Sequential Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: May 2021

Completion Date: May 2022

Last  Posted Date: June 24, 2019

Location: Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China

Website Link: https://ClinicalTrials.gov/show/NCT03917043

Was this article helpful?
Dislike 0